CFP BioConnect AG – now ACXIT Capital Partners – advises cerbomed GmbH on financing and strategic collaboration
September 2012. CFP BioConnect – now ACXIT Capital Partners – acted as sole financial advisor to cerbomed GmbH (cerbomed, the „Company“), based in Erlangen, in a financing round led by US company Cyberonics, Inc. (NASDAQ: CYBX), the market leader in medical devices for the treatment and management of epilepsy. The initial investment of Cyberonics will amount to €2 million, but could be increased to up to €5.5 million, once certain milestones are achieved.
Cerbomed is a privately held company developing a transcutaneous (non-invasive) vagus nerve stimulation („t-VNS®“) technology for the treatment of drug-resistant epilepsy, but also for a variety of other neurological disorders, including migraine and depression. The NEMOS® t-VNS® device received CE Mark approval for the indications epilepsy, depression and pain in Europe, and is already commercially available in Germany and Austria.
Along with the above mentioned minority investment, Cyberonics was granted an option to sell and distribute the NEMOS® system worldwide in the epilepsy indication. Furthermore, Cyberonics will be represented on cerbomed’s Advisory Board. The proceeds from this funding round will be used to support the Company’s ongoing clinical trial in epilepsy in Germany. Other investors participating in this round are existing investors MIG Funds, S-Refit and state-owned KfW Banking Group.
Andreas Hartlep, CEO of cerbomed, commented: „We are extremely pleased having attracted Cyberonics, the world market leader in vagus nerve stimulation („VNS“) as our strategic global partner in the epilepsy indication and to welcome them as an additional shareholder. We feel that this move by Cyberonics is a very strong validation of our technology. We have been impressed with the high quality advice we have received from CFP BioConnect, our financial advisor on this complex transaction. CFP turned out to be the right partner for us given their broad expertise on financing and M&A in the Life Sciences arena“.
This transaction further enhances CFP BioConnect’s track record in the medical technology sector. It also demonstrates that CFP group has a truly global reach, not only among financial investors, but also with respect to gaining access to industrial companies with an interest to invest in emerging technologies.
ACXIT Capital Partners is a leading independent corporate finance and investment advisory firm for mid-market clients and entrepreneurs in Europe and beyond. Since 1998, ACXIT offers its clients comprehensive corporate finance advisory services including M&A and capital markets advisory as well as restructuring, equity/debt and strategic advisory. As an independent, privately owned firm we maintain offices and representations in Frankfurt, Berlin, Munich, Leipzig, Zurich, Hong Kong and New York, as well as strong alliances in France, China and India. (www.acxit.com)
ACXIT Capital Holding GmbH
Bockenheimer Landstraße 24
60323 Frankfurt am Main
Dr. Hartmut Vennen
Senior Managing Director, Strategic Communications
Park Tower | Bockenheimer Anlage 44
60322 Frankfurt am Main
Phone: +49 69 92037 137
Mobile: +49 160 895 5858